AIM: To retrospectively analyze the pathological outcomes of patients meeting the Prostate Cancer Research International Active Surveillance (PRIAS) criteria who had undergone radical prostatectomy (RP). PATIENTS AND METHODS: Out of 2014 patients recruited for minimally invasive RP between 2008 and 2014 in 7 centers, 226 (11.2%) met the modified PRIAS criteria (clinical stage T1c/T2, PSA <10 ng/ml, 1--2 positive biopsy cores and Gleason score < 6). RESULTS: At pathological evaluation, Gleason score upgrade was reported in 47.3% of patients; 74 (32.7%), 10 (4.4%), 9 (3.9%) patients showed RP Gleason sum 7, 8 and 9, respectively. Upstaging was reported in 135 patients (59.7%). 12 (5.3%) and 4 (1.7 %) patients had T3a and T3b pathological stage respectively. CONCLUSIONS: Notwithstanding the PRIAS criteria can identify some PCa patients as low--risk, at pathological evaluation some of them harbored intermediate-- or high--risk disease. According to our data, patients eligible for AS should be carefully counseled about possible disease understaging.
Multicenter analysis of pathological outcomes of patients eligible for active surveillance according to PRIAS criteria / Grasso, A. A.; Cozzi, G.; De Lorenzis, E.; Ceruti, C.; Crivellaro, S.; Falsaperla, M.; Minervini, A.; Masieri, L.; Serni, S.; Porreca, A.; Zaramella, S.; Rocco, Bernardo Maria Cesare. - In: MINERVA UROLOGICA E NEFROLOGICA. - ISSN 0393-2249. - 68:3(2016), pp. 237-241.
Multicenter analysis of pathological outcomes of patients eligible for active surveillance according to PRIAS criteria
ROCCO, Bernardo Maria Cesare
2016
Abstract
AIM: To retrospectively analyze the pathological outcomes of patients meeting the Prostate Cancer Research International Active Surveillance (PRIAS) criteria who had undergone radical prostatectomy (RP). PATIENTS AND METHODS: Out of 2014 patients recruited for minimally invasive RP between 2008 and 2014 in 7 centers, 226 (11.2%) met the modified PRIAS criteria (clinical stage T1c/T2, PSA <10 ng/ml, 1--2 positive biopsy cores and Gleason score < 6). RESULTS: At pathological evaluation, Gleason score upgrade was reported in 47.3% of patients; 74 (32.7%), 10 (4.4%), 9 (3.9%) patients showed RP Gleason sum 7, 8 and 9, respectively. Upstaging was reported in 135 patients (59.7%). 12 (5.3%) and 4 (1.7 %) patients had T3a and T3b pathological stage respectively. CONCLUSIONS: Notwithstanding the PRIAS criteria can identify some PCa patients as low--risk, at pathological evaluation some of them harbored intermediate-- or high--risk disease. According to our data, patients eligible for AS should be carefully counseled about possible disease understaging.Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris